| dc.description.abstract | Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) bacterium, a
nosocomial pathogen is a global emergence of multidrug resistant strains leading to a
wide variety of nosocomial infections in humans. A.baumannii are reported that no longer
susceptible either to broad-spectrum cephalosporins, aminoglycosides, fluoroquinolones
or even carbapenem – the antibiotics group that exhibit good activity against this
bacteria. In this study, antibiotic susceptibility of Acinetobacter baumannii showed a high
level of resistance with Meropenem alone (susceptibility rate was only 0.6% MIC at
concentration of 2 µg/mL). However, the MDR A. baumannii is still susceptible to Colistin
alone with more than 94% MIC at ≤ 2 µg/mL. Sulbactam recently is receiving renewed
interest in treating Acinetobacter strains by combined this agent with a beta-lactamase
susceptible antibiotic. Therefore these 3 antibiotics were considered as combination of
Meropenem+Colistin and Meropenem+Sulbactam to demonstrate the synergistic
antibacterial effects, the antibacterial activitites of Meropenem and Sulbactam and
prevent toxicity concerns of Colistin of each combination, as a better treatment for this
multidrug resistant strains. Thus, the susceptible antibiotics were used in the
Checkerboard Dilution assay which the ΣFIC results showed a very high synergistic
efficacy 91% in combination Meropenem+Sulbactam and 91.43% in
Meropenem+Colistin. This synergistic effect has made 97.48% of Meropenem resistant
isolates became sensible to Meropenem in Meropenem+Sulbactam combination, and
99.37% in Meropenem+Colistin combination. To recapitulate briefly, the combination
between Sulbactam, Colistin and Meropenem has ability to against the extremely drugresistant Acinetobacter baumannii strains. | en_US |
